• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Bioventus Inc.

    5/29/26 7:58:50 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email
    SD 1 a2026conflictmineralsformsd.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM SD
     
    SPECIALIZED DISCLOSURE REPORT
     
    Bioventus Inc.
    (Exact name of registrant as specified in charter)
     
    Delaware 001-37844 81-0980861
    (State or other jurisdiction
    of incorporation or organization)
     
    (Commission File Number)
     
    (IRS Employer
    Identification Number)
    4721 Emperor Boulevard, Suite 100, Durham, North Carolina27703
    (Address of principal executive offices)(Zip Code)
    Mike Crowe, Senior Vice President—Operations; (919) 474-6700
    (Name and telephone number, including area code, of the person to contact in connection with this report)


    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:
    XRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025
    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _______.





    Section 1Conflict Minerals Disclosure
    Item 1.01    Conflict Minerals Disclosure and Report
    Conflict Minerals Disclosure
    A copy of Bioventus Inc.’s Conflict Minerals Report for the calendar year ended December 31, 2025 is filed as Exhibit 1.01 hereto and is publicly available at https://ir.bioventus.com/. The content of our website as referred to in this Form SD is included for general information only and is not incorporated by reference in this Form SD.
    Item 1.02    Exhibit
    The Conflict Minerals Report as required by Item 1.01 is filed as Exhibit 1.01 to this Form.
    Section 3Exhibits
    Item 3.01    Exhibits
    Exhibit 1.01
    Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.
    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    BIOVENTUS INC.
    Date: May 29, 2026By:/s/ Mike Crowe
    Mike Crowe, Senior Vice President—Operations

    Get the next $BVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    3/27/2026$14.00Market Outperform
    CJS Securities
    2/9/2026$13.00Outperform
    Barrington Research
    7/7/2025$12.00Overweight
    Cantor Fitzgerald
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    8/20/24 6:16:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

    Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome

    6/2/26 9:00:00 AM ET
    $BVS
    $IART
    $MDXG
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference

    DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 4:00 p.m. ET. A live webcast of the presentation will be available on the "Investors" section of the Company's website at www.bioventus.com and will be available for replay on that site following the event. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a diffe

    6/2/26 7:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

    Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl

    5/22/26 10:31:00 AM ET
    $BVS
    $EOLS
    $IART
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CJS Securities initiated coverage on Bioventus with a new price target

    CJS Securities initiated coverage of Bioventus with a rating of Market Outperform and set a new price target of $14.00

    3/27/26 9:18:56 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Barrington Research initiated coverage on Bioventus with a new price target

    Barrington Research initiated coverage of Bioventus with a rating of Outperform and set a new price target of $13.00

    2/9/26 8:08:39 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on Bioventus with a new price target

    Cantor Fitzgerald initiated coverage of Bioventus with a rating of Overweight and set a new price target of $12.00

    7/7/25 8:17:29 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    SEC Filings

    View All

    SEC Form SD filed by Bioventus Inc.

    SD - Bioventus Inc. (0001665988) (Filer)

    5/29/26 7:58:50 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Bioventus Inc. (0001665988) (Filer)

    5/21/26 4:58:18 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Bioventus Inc.

    10-Q - Bioventus Inc. (0001665988) (Filer)

    5/6/26 7:48:38 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Cowdy Philip G.

    4/A - Bioventus Inc. (0001665988) (Issuer)

    4/14/26 6:19:48 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by Cowdy Philip G.

    4/A - Bioventus Inc. (0001665988) (Issuer)

    4/14/26 6:19:27 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Singleton Mark Leonard

    4 - Bioventus Inc. (0001665988) (Issuer)

    4/14/26 6:18:58 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    11/8/24 9:13:26 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    7/15/24 5:15:58 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    2/14/24 4:51:41 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bioventus Appoints Mark Singleton as Chief Financial Officer

    DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si

    2/28/22 7:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Appoints Michelle McMurry-Heath to Board of Directors

    DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex

    12/21/21 9:25:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Financials

    Live finance-specific insights

    View All

    Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

    DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market opens on Wednesday, May 6, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's websi

    4/28/26 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

    DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

    2/24/26 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025

    DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web

    10/28/25 7:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care